Quantum Biopharma Ltd.

Quantum Biopharma Ltd. has filed an amendment to its Form 6-K report, originally submitted on March 30, 2026. This amendment, filed on September 8, 2026, serves solely to incorporate Exhibit 99.1 into the company's Registration Statement on Form F-3. No other changes were made to the original report. The filing was executed by CFO Donal Carroll.

Quantum Biopharma Ltd. reported a reduced net loss of $16.85 million for the first half of 2026, an improvement from $18.51 million in the prior year. The company significantly increased its cash and cash equivalents to $3.65 million and digital assets to $5.89 million. Operating expenses decreased, and cash used in operating activities was notably lower. The company continues its biopharmaceutical R&D and has expanded its treasury to include cryptocurrency investments.

Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302). This approval allows the company to immediately advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical development. Lucid-MS is designed to provide neuroprotection through the inhibition of demyelination, addressing a significant unmet medical need in the progressive forms of MS, a market projected to reach $1.31 billion by 2026.

Quantum BioPharma Ltd. announced the closing of a debt settlement totaling CAD$123,487.43. The settlement was made through the issuance of 30,948 Class B subordinate voting shares to creditors and insiders at a deemed price of CAD$3.99 per share. The company, focused on neurodegenerative, metabolic, and alcohol misuse disorders, noted that these shares are not registered under the U.S. Securities Act.

Quantum BioPharma Ltd. announced its board of directors approved the settlement of CAD$123,487.43 owed to arm’s length creditors and insiders. This debt will be settled through the issuance of Class B subordinate voting shares at a deemed price based on the lower of CAD$4.26 or the closing price on the Canadian Securities Exchange. The company is a biopharmaceutical firm developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, and also holds a 19.84% stake in Unbuzzd Wellness Inc., receiving royalties from its sales.

Quantum Biopharma Ltd. announced it has retained FinnCom, Inc. for a six-month contract, starting June 24, 2026, to provide marketing and investor awareness services. The agreement includes an initial payment of USD 20,500 and six subsequent monthly payments of USD 25,000, totaling USD 170,500. FinnCom, an arm's-length firm, will focus on corporate branding, social media, and advertising initiatives.

Quantum BioPharma Ltd. announced that its patented, first-in-class drug candidate, Lucid-MS, is preparing to enter Phase 2 clinical trials for Multiple Sclerosis. Lucid-MS takes a novel approach by directly targeting the myelin sheath, which is destroyed by MS, and has shown to prevent and reverse myelin degradation in preclinical models. This development was featured in an editorial by BioMedWire, highlighting the potential to address a significant unmet medical need. Additionally, Quantum BioPharma holds a 19.84% stake in Unbuzzd Wellness Inc. and receives royalty payments from sales of UNBUZZD(TM).

Quantum BioPharma Ltd. announced it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC. The agreement, effective June 8, 2026, is for a period of six months and includes services such as company profiling, media distribution, digital community building, and lead generation campaigns. The total fee for these services is US$250,000.

Quantum BioPharma Ltd. has entered into a 6-month investor relations and consulting services agreement with Stocks.news through IR Agency LLC, effective June 8, 2026. The company will pay a fee of US$250,000 for services including creating company profiles, media distribution, digital community building, marketing, and lead generation. The agency is an arm's-length party and does not hold any equity interest in Quantum BioPharma.

Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) placed its Investigational New Drug (IND) application for Lucid-21-302 (Lucid-MS), a drug candidate for multiple sclerosis, on clinical hold. The company received correspondence on May 28, 2026, requesting additional information. Quantum BioPharma believes the issues are addressable and plans to work with the FDA to submit a response, while also withdrawing all previously disclosed timelines for the program. Additionally, Dr. Lakshmi P. Kotra resigned as a director and from all positions, effective June 1, 2026, but will remain as a senior clinical advisor.